Download PDF
Thromb Haemost 1995; 74(03): 997
DOI: 10.1055/s-0038-1649867
Letter to the Editor
Schattauer GmbH Stuttgart

Risk of Inhibitor Development after Intermediate Purity Coagulation Factor Concentrates: Is It Truly Low?

P M Mannucci
Angelo Bianchi Bonomi, Hemophilia and Thrombosis Center, Institute of Internal Medicine, University of Milan, Italy
› Author Affiliations
Further Information

Publication History

Received 10 May 1995

Accepted 22 May 1995

Publication Date:
09 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints
 

  • References

  • 1 Schimpf K, Schwarz HP, Kunschak M. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex. Thromb Haemost 1995; 73: 546-556
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Roberts HR, Cromartie R. Overview of inhibitors to factors VIII and IX. Progr Clin Biol Res 1984; 150: 1-19
    PubMedGoogle Scholar
  • 3 Hanley JA, Lippman-Hand A. If nothing is wrong, is everything all right? Interpreting studies with zero numerators. JAMA 1983; 249: 1743-1745
    CrossrefPubMedGoogle Scholar
  • 4 Briät R, Rosendaal FR, Kreuz W, Rasi V, Peerlinck K, Vermylen J, Ljung R, Rocino A, Addiego J, Lorenzo JI, Pabinger I. High titer inhibitors in severe haemophilia A: a meta-analysis based on eight long-term follow up studies concerning inhibitors associated with crude or intermediate purity factor VIII products. Thromb Haemost 1994; 72: 162-163
    Article in Thieme ConnectPubMedGoogle Scholar